JP2019521139A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521139A5 JP2019521139A5 JP2019501575A JP2019501575A JP2019521139A5 JP 2019521139 A5 JP2019521139 A5 JP 2019521139A5 JP 2019501575 A JP2019501575 A JP 2019501575A JP 2019501575 A JP2019501575 A JP 2019501575A JP 2019521139 A5 JP2019521139 A5 JP 2019521139A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- composition
- atoms
- compound
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 216
- 150000001875 compounds Chemical class 0.000 claims description 120
- 238000010362 genome editing Methods 0.000 claims description 72
- 210000004027 cells Anatomy 0.000 claims description 64
- 125000001153 fluoro group Chemical group F* 0.000 claims description 54
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 54
- 229910052731 fluorine Inorganic materials 0.000 claims description 49
- WNLRTRBMVRJNCN-UHFFFAOYSA-N Adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 48
- 102000004169 proteins and genes Human genes 0.000 claims description 42
- 108090000623 proteins and genes Proteins 0.000 claims description 42
- 150000007523 nucleic acids Chemical class 0.000 claims description 41
- 150000003839 salts Chemical class 0.000 claims description 41
- 239000011780 sodium chloride Substances 0.000 claims description 41
- 229910052739 hydrogen Inorganic materials 0.000 claims description 40
- 239000001257 hydrogen Substances 0.000 claims description 40
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 38
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 36
- 125000000623 heterocyclic group Chemical group 0.000 claims description 36
- 150000002431 hydrogen Chemical class 0.000 claims description 36
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 36
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims description 32
- 108020004707 nucleic acids Proteins 0.000 claims description 32
- 239000001361 adipic acid Substances 0.000 claims description 25
- 235000011037 adipic acid Nutrition 0.000 claims description 25
- 230000014509 gene expression Effects 0.000 claims description 24
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 22
- 229910052805 deuterium Inorganic materials 0.000 claims description 22
- 238000003776 cleavage reaction Methods 0.000 claims description 21
- 229920000033 CRISPR Polymers 0.000 claims description 20
- 238000010354 CRISPR gene editing Methods 0.000 claims description 20
- 230000037361 pathway Effects 0.000 claims description 20
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 18
- 125000002757 morpholinyl group Chemical group 0.000 claims description 18
- 125000003566 oxetanyl group Chemical group 0.000 claims description 18
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 18
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 108009000261 Non-homologous end joining Proteins 0.000 claims description 14
- 229920002391 Guide RNA Polymers 0.000 claims description 12
- 108020005004 Guide RNA Proteins 0.000 claims description 12
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 10
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 10
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 10
- 239000012190 activator Substances 0.000 claims description 10
- 230000003612 virological Effects 0.000 claims description 10
- 108010082319 CRISPR-Associated Protein 9 Proteins 0.000 claims description 8
- 101700080605 NUC1 Proteins 0.000 claims description 8
- 101700056051 cas9 Proteins 0.000 claims description 8
- 101700006494 nucA Proteins 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 230000001629 suppression Effects 0.000 claims description 7
- 230000000295 complement Effects 0.000 claims description 6
- 239000005711 Benzoic acid Substances 0.000 claims description 5
- 235000010233 benzoic acid Nutrition 0.000 claims description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 5
- 239000001530 fumaric acid Substances 0.000 claims description 5
- 239000011976 maleic acid Substances 0.000 claims description 5
- 239000001384 succinic acid Substances 0.000 claims description 5
- 102200028136 CSN1S1 D10A Human genes 0.000 claims description 4
- 208000009889 Herpes Simplex Diseases 0.000 claims description 4
- 230000022131 cell cycle Effects 0.000 claims description 4
- 238000002744 homologous recombination Methods 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 230000001404 mediated Effects 0.000 claims description 4
- 238000002703 mutagenesis Methods 0.000 claims description 4
- 231100000350 mutagenesis Toxicity 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 241000432074 Adeno-associated virus Species 0.000 claims description 3
- 241000713666 Lentivirus Species 0.000 claims description 3
- 241000700584 Simplexvirus Species 0.000 claims description 3
- 230000002103 transcriptional Effects 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 229920002676 Complementary DNA Polymers 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 210000004748 cultured cells Anatomy 0.000 claims description 2
- 230000003247 decreasing Effects 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 229920000023 polynucleotide Polymers 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 230000001360 synchronised Effects 0.000 claims description 2
- -1 2 Chemical class 0.000 claims 12
- 238000005245 sintering Methods 0.000 claims 4
- 230000001177 retroviral Effects 0.000 claims 1
- 108091006090 transcriptional activators Proteins 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662361961P | 2016-07-13 | 2016-07-13 | |
US201662361781P | 2016-07-13 | 2016-07-13 | |
US62/361,781 | 2016-07-13 | ||
US62/361,961 | 2016-07-13 | ||
PCT/US2017/041979 WO2018013840A1 (en) | 2016-07-13 | 2017-07-13 | Methods, compositions and kits for increasing genome editing efficiency |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019521139A JP2019521139A (ja) | 2019-07-25 |
JP2019521139A5 true JP2019521139A5 (US07794700-20100914-C00152.png) | 2020-08-20 |
JP7033583B2 JP7033583B2 (ja) | 2022-03-10 |
Family
ID=59388213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019501575A Active JP7033583B2 (ja) | 2016-07-13 | 2017-07-13 | ゲノム編集効率を高めるための方法、組成物及びキット |
Country Status (9)
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
CA2963820A1 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
EP3786294A1 (en) | 2015-09-24 | 2021-03-03 | Editas Medicine, Inc. | Use of exonucleases to improve crispr/cas-mediated genome editing |
CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
US11597924B2 (en) | 2016-03-25 | 2023-03-07 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
EP3443086B1 (en) | 2016-04-13 | 2021-11-24 | Editas Medicine, Inc. | Cas9 fusion molecules, gene editing systems, and methods of use thereof |
US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
EP3529347A1 (en) | 2016-10-19 | 2019-08-28 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
AR111874A1 (es) | 2017-05-18 | 2019-08-28 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina |
AR111807A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2 |
UA125123C2 (uk) | 2017-05-18 | 2022-01-12 | Ідорсія Фармасьютікалз Лтд | Фенільні похідні як модулятори pge2 рецепторів |
CA3060394A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as pge2 receptor modulators |
EP3652312A1 (en) | 2017-07-14 | 2020-05-20 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
BR112020009889A2 (pt) | 2017-12-14 | 2020-11-03 | Flodesign Sonics, Inc. | acionador e controlador de transdutor acústico |
CA3088788A1 (en) * | 2018-01-17 | 2019-07-25 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
WO2019224603A1 (en) | 2018-05-24 | 2019-11-28 | Crispr Therapeutics Ag | Methods and compositions for efficient gene deletion |
CN110592141B (zh) * | 2018-06-13 | 2023-07-07 | 中国科学院上海有机化学研究所 | 用于调控基因编辑效率的化合物及其应用 |
CN108949830B (zh) * | 2018-08-03 | 2021-11-26 | 福州大学 | 一种在鱼类中实现基因组编辑、精确定点基因敲入的方法 |
CA3123151A1 (en) * | 2018-12-12 | 2020-06-18 | Depixus | Method of nucleic acid enrichment using site-specific nucleases followed by capture |
WO2020205664A1 (en) * | 2019-03-29 | 2020-10-08 | Youhealth Biotech, Limited | Compositions and methods for cellular reprogramming to rescue visual function |
US20220220472A1 (en) * | 2019-05-06 | 2022-07-14 | The Regents Of The University Of Michigan | Targeted therapy |
BR112022003505A2 (pt) | 2019-08-27 | 2022-05-24 | Vertex Pharma | Composições e métodos para tratamento de distúrbios associados a dna repetitivo |
CN112553330B (zh) * | 2019-09-26 | 2022-07-26 | 首都医科大学附属北京友谊医院 | 新型肿瘤相关转录因子zscan16及其在抑制肿瘤中的应用 |
WO2021087358A1 (en) | 2019-11-01 | 2021-05-06 | Sangamo Therapeutics, Inc. | Gin recombinase variants |
CN110863011A (zh) * | 2019-11-28 | 2020-03-06 | 浙江大学 | 干扰猪crtc3表达的质粒及腺病毒的构建方法及其用途 |
CN112877364B (zh) * | 2019-11-29 | 2023-07-28 | 中国医学科学院药物研究所 | 软骨下骨细胞向关节软骨细胞直接转化的重编程诱导方案 |
CN111088290B (zh) * | 2019-12-30 | 2021-10-08 | 同济大学 | 一种杜鹃素在基因编辑中的应用 |
JP2023515907A (ja) * | 2020-02-19 | 2023-04-14 | 国立大学法人京都大学 | ゲノム編集された細胞の製造方法及びそのためのキット |
GB202008201D0 (en) * | 2020-06-01 | 2020-07-15 | Neophore Ltd | Inhibitor compounds |
CN113897357A (zh) * | 2020-07-06 | 2022-01-07 | 北京大学 | Twist1基因编辑系统及其在制备治疗三阴性乳腺癌的产品中的应用 |
CN114717232A (zh) * | 2020-12-22 | 2022-07-08 | 未来智人再生医学研究院(广州)有限公司 | 表达irf-1靶向抑制因子的多能干细胞及其衍生物与应用 |
CN112750498B (zh) * | 2020-12-30 | 2022-06-24 | 同济大学 | 靶向逆转录引物结合位点从而抑制hiv病毒复制的方法 |
TW202302848A (zh) | 2021-02-26 | 2023-01-16 | 美商維泰克斯製藥公司 | 以crispr/sacas9治療第1型肌強直性營養不良之組合物及方法 |
EP4298221A1 (en) | 2021-02-26 | 2024-01-03 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/slucas9 |
CN113373148B (zh) * | 2021-06-16 | 2022-08-26 | 中国人民解放军军事科学院军事医学研究院 | 一种调控app表达的靶标位点序列及其在防治ad上的应用 |
WO2023018637A1 (en) | 2021-08-09 | 2023-02-16 | Vertex Pharmaceuticals Incorporated | Gene editing of regulatory elements |
CA3236182A1 (en) * | 2021-10-29 | 2023-05-04 | Z. Josh Huang | Compositions and systems for rna-programable cell editing and methods of making and using same |
CN114277119B (zh) * | 2021-12-09 | 2023-05-16 | 浙江大学医学院附属邵逸夫医院 | 一种环状RNA circ-Arsb在制备防治骨质疏松产品中的应用 |
WO2023120530A1 (ja) * | 2021-12-24 | 2023-06-29 | 国立大学法人大阪大学 | 相同組換えを利用したゲノム編集細胞の製造方法 |
WO2023150555A1 (en) * | 2022-02-01 | 2023-08-10 | The Brigham And Women's Hospital, Inc. | Generation of brown adipocytes from human pluripotent stem cells |
CN114524811A (zh) * | 2022-03-16 | 2022-05-24 | 中国人民解放军军事科学院军事医学研究院 | Lxh0307、lxh0308作为基因编辑的小分子抑制剂及其应用 |
CN114685494B (zh) * | 2022-03-16 | 2024-04-16 | 中国人民解放军军事科学院军事医学研究院 | SpCas9抑制剂的合成制备方法及其应用 |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US789538A (en) | 1904-11-11 | 1905-05-09 | Colin E Ham | Dumb-bell. |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5487994A (en) | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
US5356802A (en) | 1992-04-03 | 1994-10-18 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease |
US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
US6242568B1 (en) | 1994-01-18 | 2001-06-05 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
WO1995019431A1 (en) | 1994-01-18 | 1995-07-20 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
AU696455C (en) | 1994-03-23 | 2006-03-02 | Case Western Reserve University | Compacted nucleic acids and their delivery to cells |
GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
JP4118327B2 (ja) | 1994-08-20 | 2008-07-16 | ゲンダック・リミテッド | Dna認識のための結合タンパク質におけるまたはそれに関連する改良 |
US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
GB2338237B (en) | 1997-02-18 | 2001-02-28 | Actinova Ltd | In vitro peptide or protein expression library |
GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
ATE466952T1 (de) | 1998-03-02 | 2010-05-15 | Massachusetts Inst Technology | Poly-zinkfinger-proteine mit verbesserten linkern |
US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
US7070934B2 (en) | 1999-01-12 | 2006-07-04 | Sangamo Biosciences, Inc. | Ligand-controlled regulation of endogenous gene expression |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
US7030215B2 (en) | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
DE60023936T2 (de) | 1999-12-06 | 2006-05-24 | Sangamo Biosciences Inc., Richmond | Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen |
AU5077401A (en) | 2000-02-08 | 2001-08-20 | Sangamo Biosciences Inc | Cells for drug discovery |
US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
AU2001263155A1 (en) | 2000-05-16 | 2001-11-26 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
US20040224385A1 (en) | 2001-08-20 | 2004-11-11 | Barbas Carlos F | Zinc finger binding domains for cnn |
US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
CN100575485C (zh) | 2002-01-23 | 2009-12-30 | 犹他大学研究基金会 | 使用锌指核酸酶的定向染色体诱变 |
US7074596B2 (en) | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
US7361635B2 (en) | 2002-08-29 | 2008-04-22 | Sangamo Biosciences, Inc. | Simultaneous modulation of multiple genes |
US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
JP4903689B2 (ja) | 2004-04-08 | 2012-03-28 | サンガモ バイオサイエンシズ インコーポレイテッド | 神経障害および神経変性症状を治療するための方法と組成物 |
JP2008506359A (ja) | 2004-04-08 | 2008-03-06 | サンガモ バイオサイエンシズ インコーポレイテッド | ジンクフィンガータンパク質による神経因性疼痛の処置 |
EP1913149A4 (en) | 2005-07-26 | 2009-08-05 | Sangamo Biosciences Inc | TARGETED INTEGRATION AND EXPRESSION OF EXOGENOUS NUCLEIC ACID SEQUENCES |
EP2213731B1 (en) | 2006-05-25 | 2013-12-04 | Sangamo BioSciences, Inc. | Variant foki cleavage half-domains |
CA2692906C (en) | 2007-06-19 | 2016-01-19 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap |
US10047346B2 (en) | 2008-08-08 | 2018-08-14 | Mayo Foundation For Medical Education And Research | Method of treating heart tissue using induced pluripotent stem cells |
JP6137596B2 (ja) | 2010-02-08 | 2017-05-31 | サンガモ セラピューティクス, インコーポレイテッド | 遺伝子操作された切断ハーフドメイン |
MX359327B (es) | 2012-02-29 | 2018-09-25 | Sangamo Biosciences Inc | Composiciones y sus usos para tratar y prevenir la enfermedad de huntington. |
NZ700928A (en) * | 2012-04-24 | 2017-06-30 | Vertex Pharma | Dna-pk inhibitors |
EP3808844A1 (en) | 2012-07-25 | 2021-04-21 | The Broad Institute, Inc. | Inducible dna binding proteins and genome perturbation tools and applications thereof |
US9181535B2 (en) | 2012-09-24 | 2015-11-10 | The Chinese University Of Hong Kong | Transcription activator-like effector nucleases (TALENs) |
KR102121086B1 (ko) * | 2012-11-01 | 2020-06-09 | 팩터 바이오사이언스 인크. | 세포에서 단백질을 발현시키는 방법들과 생성물들 |
WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
EP3434776A1 (en) | 2012-12-12 | 2019-01-30 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
EP2848690B1 (en) | 2012-12-12 | 2020-08-19 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
ES2786193T3 (es) | 2012-12-12 | 2020-10-09 | Broad Inst Inc | Modificación por tecnología genética y optimización de sistemas, métodos y composiciones enzimáticas mejorados para la manipulación de secuencias |
ES2553782T3 (es) | 2012-12-12 | 2015-12-11 | The Broad Institute, Inc. | Ingeniería de sistemas, métodos y composiciones de guía optimizadas para manipulación de secuencias |
EP2931899A1 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
EP3252160B1 (en) | 2012-12-12 | 2020-10-28 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
MX2015007550A (es) | 2012-12-12 | 2017-02-02 | Broad Inst Inc | Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas. |
DK2931898T3 (en) | 2012-12-12 | 2016-06-20 | Massachusetts Inst Technology | CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
CN113563476A (zh) * | 2013-03-15 | 2021-10-29 | 通用医疗公司 | 遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向 |
US11332719B2 (en) | 2013-03-15 | 2022-05-17 | The Broad Institute, Inc. | Recombinant virus and preparations thereof |
US20160040155A1 (en) | 2013-04-16 | 2016-02-11 | University Of Washington Through Its Center For Commercialization | Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering |
ES2777217T3 (es) | 2013-06-17 | 2020-08-04 | Broad Inst Inc | Suministro, modificación y optimización de sistemas de guía en tándem, métodos y composiciones para la manipulación de secuencias |
EP3011033B1 (en) | 2013-06-17 | 2020-02-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
KR20160034901A (ko) | 2013-06-17 | 2016-03-30 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작에 최적화된 crispr-cas 이중 닉카아제 시스템, 방법 및 조성물 |
SG11201510286QA (en) | 2013-06-17 | 2016-01-28 | Broad Inst Inc | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components |
DK3011032T3 (da) | 2013-06-17 | 2020-01-20 | Broad Inst Inc | Fremføring, modificering og optimering af systemer, fremgangsmåder og sammensætninger til målretning mod og modellering af sygdomme og forstyrrelser i postmitotiske celler |
DK3011031T3 (da) | 2013-06-17 | 2020-12-21 | Broad Inst Inc | Fremføring og anvendelse af crispr-cas-systemerne, vektorer og sammensætninger til levermålretning og -terapi |
EP3011035B1 (en) | 2013-06-17 | 2020-05-13 | The Broad Institute, Inc. | Assay for quantitative evaluation of target site cleavage by one or more crispr-cas guide sequences |
KR101448678B1 (ko) | 2013-08-12 | 2014-10-08 | 김형기 | 단추 재봉실의 뿌리감기 장치 |
US20150095137A1 (en) | 2013-09-27 | 2015-04-02 | Stout Partners LP | System and apparatus for effective coordination and scheduling of accesses to rate limited online sites to obtain data for use in assessing social metrics based on domain tailored evaluation of social media exposure |
WO2015048577A2 (en) | 2013-09-27 | 2015-04-02 | Editas Medicine, Inc. | Crispr-related methods and compositions |
PT3424920T (pt) | 2013-10-17 | 2020-07-07 | Vertex Pharma | Co-cristais de (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolina-4-carboxamida e derivados deuterados dos mesmos como inibidores de adn-pk |
EP3686279B1 (en) | 2014-08-17 | 2023-01-04 | The Broad Institute, Inc. | Genome editing using cas9 nickases |
KR20230070319A (ko) | 2014-11-21 | 2023-05-22 | 리제너론 파마슈티칼스 인코포레이티드 | 쌍 형성된 가이드 rna를 사용하는 표적화된 유전자 변형을 위한 방법 및 조성물 |
-
2017
- 2017-07-13 EP EP22207527.7A patent/EP4219462A1/en active Pending
- 2017-07-13 ES ES17743188T patent/ES2938210T3/es active Active
- 2017-07-13 US US16/317,314 patent/US11124805B2/en active Active
- 2017-07-13 EP EP17743188.9A patent/EP3484870B1/en active Active
- 2017-07-13 MA MA045670A patent/MA45670A/fr unknown
- 2017-07-13 AU AU2017295720A patent/AU2017295720B2/en active Active
- 2017-07-13 WO PCT/US2017/041979 patent/WO2018013840A1/en unknown
- 2017-07-13 CN CN201780052987.3A patent/CN109863143B/zh active Active
- 2017-07-13 JP JP2019501575A patent/JP7033583B2/ja active Active
- 2017-07-13 CA CA3030783A patent/CA3030783A1/en active Pending
-
2021
- 2021-08-20 US US17/407,421 patent/US20220106615A1/en active Pending
- 2021-09-17 AU AU2021232813A patent/AU2021232813B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019521139A5 (US07794700-20100914-C00152.png) | ||
EP3371207B1 (en) | Nucleic acids, peptides and methods | |
US20230183693A1 (en) | Reducing intron retention | |
AU2018264115B2 (en) | Methods and products for expressing proteins in cells | |
EP3368687B1 (en) | Compositions and methods for targeting cancer-specific sequence variations | |
ES2934810T3 (es) | Moléculas químicas que inhiben el mecanismo de empalme para tratar enfermedades causadas por anomalías de empalme | |
JP2023517187A (ja) | ゲノムを調節するための方法及び組成物 | |
JP2016538885A5 (US07794700-20100914-C00152.png) | ||
JP2019515914A5 (US07794700-20100914-C00152.png) | ||
JP2020536888A5 (US07794700-20100914-C00152.png) | ||
JP2018509143A5 (US07794700-20100914-C00152.png) | ||
WO2018067991A1 (en) | Modulation of novel immune checkpoint targets | |
BR112020018364A2 (pt) | Sistemas e métodos para o tratamento de hemoglobinopatias | |
JP2020537545A (ja) | mRNAの細胞内送達のためのペプチドおよびナノ粒子 | |
WO2017075465A1 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 | |
JP7373170B2 (ja) | ジヒドロオロト酸デヒドロゲナーゼ阻害のための方法及び組成物 | |
US20230026259A1 (en) | Ca2 compositions and methods for tunable regulation | |
JP2020517270A5 (US07794700-20100914-C00152.png) | ||
JPWO2019143675A5 (US07794700-20100914-C00152.png) | ||
WO2021216503A1 (en) | Aav delivery system for lung cancer treatment | |
CA3146702A1 (en) | Aav capsid variants for targeting human glioblastoma cells | |
WO2021142376A1 (en) | Compositions and methods for tunable regulation of transcription | |
US20070036721A1 (en) | Methods and compositions for in vivo inflammation monitoring | |
JPWO2019143677A5 (US07794700-20100914-C00152.png) | ||
CA3208497A1 (en) | Small molecule-regulated gene expression system |